Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : E7386,Lenvatinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : PRISM BioLab
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : E7386 is a CBP/β-catenin inhibitor that inhibits CBP and β-catenin protein-protein interactions and regulates the Wnt signal-dependent gene expression is expected to suppress tumor.
Brand Name : E7386
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 01, 2021
Lead Product(s) : E7386,Lenvatinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : PRISM BioLab
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?